Singapore Lymphoma Study: Insights into Lymphoma Epidemiology and Outcomes in Singapore
6 March 2026
Main Applicant – Dr Woo Xing Yi, Senior Principal Scientist, Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR)
Lymphomas is the 6th most common cancer in Singapore. This study focuses on two major aims: first, to analyse population-level incidence and survival trends in lymphoma subtypes in Singapore over time; and second, to identify the key lifestyle and clinical factors that influence patient outcomes. First, we will utilize data from Singapore Cancer Registry to explore trends in lymphoma subtypes compared to other cancer types to better understand their prevalence, incidence, and distribution longitudinally and across various demographics.
Subsequently, we aim to link health and socioeconomic records in MOH TRUST to investigate trends in lymphoma subtypes to better understand their prevalence, incidence, and distribution longitudinally and across various demographics. This analysis will also reveal specific clinical and sociodemographic drivers including disease pathology, treatment regimens, as well as ethnicity, socioeconomic status and geographic factors on patient outcomes.